Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf051 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2025. Verfasst von Nai-Jung Chiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, 112201 Taipei, Taiwan. Hauptthemen laut MEDLINE: Deoxycytidine, Neoplasms, Antimetabolites, Antineoplastic. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innopharmax Inc.
Abstract (Originalsprache)
Background
D07001-F4 is an absorption-enhanced oral gemcitabine developed in liquid formulation and adjusted to D07001-softgel capsules. We conducted 2 phase 1 studies to evaluate the dose-limiting toxicity (DLT), pharmacokinetics (PK), and maximum tolerated dose (MTD) of the 2 formulations of D07001 in patients with advanced solid tumors. Materials and methods Initially, patients received escalating doses (2–80 mg) of D07001-F4 thrice a week for 2 weeks, followed by 1-week rest. Since no DLT was observed in the phase 1 study, the phase 1b study was conducted with D07001-softgel capsules (dose range: 40–120 mg) in patients with refractory gastrointestinal malignancies. A bridging dose of 40 mg was administered in the phase 1b study to achieve an equivalent intake of 80 mg of D07001-F4.
Results
Fifty-three patients (phase 1, n = 34; phase 1b, n = 19) were enrolled. The mean oral bioavailability of D07001-F4 was ~39%. Two patients receiving 120 mg of D07001-softgel capsules experienced grade 3 hepatotoxicity and anorexia, respectively. Therefore, an additional 100 mg dose was tested and determined as the MTD. The Cmax and area under the curve of gemcitabine and its metabolite, 2′, 2′-difluoro deoxyuridine, have a dose-dependent manner and comparable between the 2 formulations. Grade ≥ 3 anorexia (10.5%) and diarrhea (10.5%) were observed in the phase 1b extension study.
Conclusion
Our study demonstrated that D07001-softgel capsules can be safely administered as continuous dosing of up to 100 mg in patients with advanced solid tumors. Further studies are warranted to determine the appropriate dose in combination with other chemotherapy drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Taipei Veterans General Hospital, 112201 Taipei, Taiwan.
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, 112304 Taipei, Taiwan.
- Department of Oncology, National Taiwan University Hospital, 100229 Taipei, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, 704302 Tainan, Taiwan.
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, 404327 Taichung, Taiwan.
- Department of Surgery, National Cheng Kung University Hospital, 704302 Tainan, Taiwan.
ORCID-Profile: Chia-Chi Lin
Förderung
- Innopharmax Inc
Zitieren
APA
Chiang, N. J., Lee, J. H., Chen, M. H., Chao, Y., Su, W. C., Bai, L. Y., Wu, S. Y., Hsu, C. H., Shan, Y. S., Li, C. P., Chen, S. H., Chung, W. P., Hao, W. H., Chen, L. T., & Lin, C. C. (2025). Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors. The Oncologist. https://doi.org/10.1093/oncolo/oyaf051
Vancouver
Chiang NJ, Lee JH, Chen MH, Chao Y, Su WC, Bai LY, et al. Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors. The Oncologist. 2025. doi:10.1093/oncolo/oyaf051
BibTeX
@article{Chiang2025,
author = {Chiang, Nai-Jung and Lee, Jih-Hsiang and Chen, Ming-Huang and Chao, Yee and Su, Wu-Chou and Bai, Li-Yuan and Wu, Shang-Yin and Hsu, Chih-Hung and Shan, Yan-Shen and Li, Chung-Pin and Chen, Shang-Hung and Chung, Wei-Pang and Hao, Wei-Hua and Chen, Li-Tzong and Lin, Chia-Chi},
title = {Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf051}
}
EUVIMED